1. Home
  2. ZURA vs IHRT Comparison

ZURA vs IHRT Comparison

Compare ZURA & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZURA
  • IHRT
  • Stock Information
  • Founded
  • ZURA 2022
  • IHRT 1974
  • Country
  • ZURA United States
  • IHRT United States
  • Employees
  • ZURA N/A
  • IHRT N/A
  • Industry
  • ZURA Biotechnology: Biological Products (No Diagnostic Substances)
  • IHRT Broadcasting
  • Sector
  • ZURA Health Care
  • IHRT Consumer Discretionary
  • Exchange
  • ZURA Nasdaq
  • IHRT Nasdaq
  • Market Cap
  • ZURA 69.9M
  • IHRT 193.4M
  • IPO Year
  • ZURA N/A
  • IHRT 2019
  • Fundamental
  • Price
  • ZURA $1.05
  • IHRT $1.67
  • Analyst Decision
  • ZURA Buy
  • IHRT Buy
  • Analyst Count
  • ZURA 7
  • IHRT 3
  • Target Price
  • ZURA $14.33
  • IHRT $2.92
  • AVG Volume (30 Days)
  • ZURA 755.8K
  • IHRT 904.5K
  • Earning Date
  • ZURA 08-08-2025
  • IHRT 08-07-2025
  • Dividend Yield
  • ZURA N/A
  • IHRT N/A
  • EPS Growth
  • ZURA N/A
  • IHRT N/A
  • EPS
  • ZURA N/A
  • IHRT N/A
  • Revenue
  • ZURA N/A
  • IHRT $3,862,595,000.00
  • Revenue This Year
  • ZURA N/A
  • IHRT N/A
  • Revenue Next Year
  • ZURA N/A
  • IHRT $5.89
  • P/E Ratio
  • ZURA N/A
  • IHRT N/A
  • Revenue Growth
  • ZURA N/A
  • IHRT 3.31
  • 52 Week Low
  • ZURA $0.97
  • IHRT $0.95
  • 52 Week High
  • ZURA $5.07
  • IHRT $2.84
  • Technical
  • Relative Strength Index (RSI)
  • ZURA 48.12
  • IHRT 57.25
  • Support Level
  • ZURA $1.10
  • IHRT $1.64
  • Resistance Level
  • ZURA $1.22
  • IHRT $1.77
  • Average True Range (ATR)
  • ZURA 0.09
  • IHRT 0.13
  • MACD
  • ZURA 0.00
  • IHRT -0.01
  • Stochastic Oscillator
  • ZURA 31.25
  • IHRT 42.11

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

About IHRT iHeartMedia Inc.

iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.

Share on Social Networks: